Development and Evaluation of Hesperetin- Loaded Solid Lipid Nano-particles
DOI:
https://doi.org/10.63682/jns.v14i31S.8795Keywords:
Solid lipid nanoparticles, Hesperetin, in-vitro drug release, Drug excipients compatibilityAbstract
The present research was based on the Development and Evaluation of Hesperetin- Loaded Solid Lipid Nano-particle. The hesperitin was obtained from the Sigma-Aldrich, India. Stearic acid, Span 20, Tweens 80 (Sigma Aldrich, India), distilled water, ethanol were procured from the local chemical shop in Haridwar, UK. In Preformulation studies, various parameters i.e., organoleptic properties, melting point, solubility, Drug excipients compatibility studies and Preparation of Standard Calibration Curve. Preparation of gallic acid- based solid lipid nanoparticles was done using spray-drying method. It was characterized for various parameters i.e., Physical appearance, Entrapment efficiency, Drug content determination, pH determination, Determination of particles size & PDI, SEM analysis, In vitro drug release and Stability studies. Hesperitin showed very poor solubility in distilled water and ethanol. Both stearic acid and cholesterol dissolved it freely. Formulations F1-F6 were observed to be clear, white and homogenous in appearance. After 6 hours, SLN 1, SLN 2, SLN 3 showed % drug release as 89.3±0.4, 92.6±0.3 and 91.4±0.2, respectively. While SLN 4 demonstrated increased % release as 92.9±0.2 %. In conclusion, among the several forms of solid lipid nanoparticles of hesperitin, F5 was found to be the most significant formulation in terms of in-vitro drug release, droplet size, and drug content. It also showed improved stability, with no significant change in pH, % drug release and physical appearances after being stored for a month.
Downloads
Metrics
References
Tyagi P, J.A. Subramony. Guidance for Industry: Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology, Food and Drug Administration (Accessed 02 Fig. 4. Schematic showing flexibility for developing immunotherapy combinations based on patient parameters such as tumor phenotype and tumor biomarker information. Journal of Controlled Release, 2018; 272:159-168.
Liu L, Q. Ye, M. Lu, Y.C. Lo, Y.H. Hsu, M.C. Wei, Y.H. Chen, S.C. Lo, S.J. Wang, D.J. Bain, C. Ho, A new approach to reduce toxicities and to improve bioavail- abilities of platinum-containing anti-cancer nanodrugs, Sci. Rep. 5 (2015) 10881.
Merisko-Liversidge E, G.G. Liversidge. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology, Adv. Drug Deliv. Rev. 63 (2011) 427-440.
Khadka P R, H. Kim, I. Kim, J. Kim, H. Kim, J. Cho, G. Yun, J. Lee, Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability, Asian J. Pharm. Sci. 9 (2014) 304–316.
Maeda H, H. Nakamura, J. Fang, The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo, Adv. Drug Deliv. Rev. 65 (2013) 71–79.
Amjad Khan, Muhammad Ikram, Jong Ryeal Hahm and Myeong Ok Kim. Antioxidant and Anti-Inflammatory Effects of Citrus Flavonoid Hesperetin: Special Focus on Neurological Disorders. Antioxidants 2020, 9(7), 609.
Hostetler, G.L.; Ralston, R.A.; Schwartz, S.J. Flavones: Food Sources, Bioavailability, Metabolism, and Bioactivity. Adv. Nutr. 2017, 8, 423–435.
Youdim, K.A.; Dobbie, M.S.; Kuhnle, G.; Proteggente, A.R.; Abbott, N.J.; Rice-Evans, C. Interaction between flavonoids and the blood-brain barrier: In vitro studies. J. Neurochem. 2003, 85, 180–192.
Hollman, P.C. Absorption, Bioavailability, and Metabolism of Flavonoids. Pharm. Biol. 2004, 42, 74–83.
Makarova, N.M. [Bioavailability and metabolism of flavonoids]. Eksp. Klin. Farmakol. 2011, 74, 33–40.
Figueira, I.; Garcia, G.; Pimpão, R.C.; Terrasso, A.; Costa, I.; Almeida, A.F.; Tavares, L.; Pais, T.F.; Pinto, P.; Ventura, M.R.; et al. Polyphenols journey through blood-brain barrier towards neuronal protection. Sci. Rep. 2017, 7, 11456.
Samiullah, Jan SU, Gul R, Jalaludin S, Asmathullah, “formulation and evaluation of transdermal patches of pseudoephedrine HCL”, International Journal of Applied Pharmaceutics, 2020,12(3), 121-127.
Chauhan SB, Saini S, “formulation and evaluation of transdermal patches of metoprolol tartrate using permeation enhancers of natural and synthetic origin”, Int J App Pharm, 2019,11(5), 293-298.
Kulkarni S. Formulation and Evaluation of Transdermal Patch for Atomoxetine hydrochloride. JDDT, 2019;9(2-A):32-5.
Jirapornchai Suksaeree, Chomnapas Chuchote. Accelerated Stability Testing of a Polyherbal Transdermal Patches Using Polyvinyl Alcohol and Hydroxypropyl Methylcelluloseas a Controlling Polymer Layer. Journal of Polymers and the Environment (2018) 26:4056–4062.
Kavitha K and More Mangesh Rajendra, Design and Evaluation of Transdermal Films of Lornoxicam, IJPBS, 2011, 2(2), 54-62.
Shalu Rani, Kamal Saroha, Navneet Syan, Pooja Mathur, Transdermal Patches A Successful Tool In Transdermal Drug Delivery System: An overview, Der Pharmacia Sinica, 2011, 2 (5), 17-29.
D NV, Shrestha N, Sharma J. Transdermal drug delivery system: An overview. Int J Res Pharm Sci. 2012;3(2):234–41.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
